Ranbaxy loses battle for Lipitor patent in Canada.

Economic Times (New Delhi, India), September, 2007

Sep. 14--NEW DELHI -- In a setback for Ranbaxy in its global battle over the patent of Lipitor, a Canadian federal court has ruled that the company's generic drug Atorvastatin infringes upon one of Pfizer's Lipitor patent. However, the court dismissed Pfizer's appeal for a prohibition order for another patent of the same drug in Canada.

"The court has ruled that Pfizer's patent covering a crystalline form of Atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy's process for making their proposed generic Atorvastatin product," a Pfizer release said. The court ruling means that Ranbaxy cannot launch Atorvastatin in Canada until Lipitor's patent (Canadian Patent Number 22,20,018) expires in July 2016.

However, the court...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.